Abacus FCF Advisors LLC Invests $608,000 in Hims & Hers Health, Inc. (NYSE:HIMS)

Abacus FCF Advisors LLC purchased a new position in shares of Hims & Hers Health, Inc. (NYSE:HIMS) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 25,145 shares of the company’s stock, valued at approximately $608,000.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Rockefeller Capital Management L.P. grew its stake in shares of Hims & Hers Health by 5.8% in the 3rd quarter. Rockefeller Capital Management L.P. now owns 33,775 shares of the company’s stock worth $622,000 after acquiring an additional 1,864 shares in the last quarter. HighTower Advisors LLC bought a new stake in Hims & Hers Health in the 3rd quarter worth about $207,000. State Street Corp increased its stake in Hims & Hers Health by 4.7% in the 3rd quarter. State Street Corp now owns 4,626,543 shares of the company’s stock valued at $85,221,000 after buying an additional 206,078 shares during the last quarter. Wellington Management Group LLP lifted its position in shares of Hims & Hers Health by 34.5% during the 3rd quarter. Wellington Management Group LLP now owns 3,444,414 shares of the company’s stock worth $63,446,000 after buying an additional 883,230 shares in the last quarter. Finally, MML Investors Services LLC purchased a new position in shares of Hims & Hers Health in the 3rd quarter worth approximately $197,000. 63.52% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

HIMS has been the subject of a number of research analyst reports. Bank of America increased their price target on Hims & Hers Health from $21.00 to $22.00 and gave the company an “underperform” rating in a research report on Tuesday, March 18th. Needham & Company LLC raised their target price on Hims & Hers Health from $31.00 to $61.00 and gave the company a “buy” rating in a research report on Tuesday, February 25th. BTIG Research initiated coverage on shares of Hims & Hers Health in a report on Tuesday, January 7th. They issued a “buy” rating and a $35.00 price target on the stock. Canaccord Genuity Group increased their price target on shares of Hims & Hers Health from $38.00 to $68.00 and gave the company a “buy” rating in a research report on Wednesday, February 19th. Finally, Piper Sandler lifted their price objective on shares of Hims & Hers Health from $24.00 to $35.00 and gave the stock a “neutral” rating in a research report on Tuesday, February 25th. Two research analysts have rated the stock with a sell rating, seven have given a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $37.31.

Insiders Place Their Bets

In other Hims & Hers Health news, CFO Oluyemi Okupe sold 11,581 shares of the company’s stock in a transaction dated Wednesday, April 2nd. The stock was sold at an average price of $29.26, for a total value of $338,860.06. Following the transaction, the chief financial officer now directly owns 124,104 shares in the company, valued at $3,631,283.04. This represents a 8.54 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Michael Chi sold 7,259 shares of Hims & Hers Health stock in a transaction dated Friday, January 10th. The shares were sold at an average price of $24.07, for a total value of $174,724.13. Following the sale, the insider now owns 193,601 shares of the company’s stock, valued at approximately $4,659,976.07. This trade represents a 3.61 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 809,806 shares of company stock worth $30,923,658 in the last three months. 17.71% of the stock is currently owned by corporate insiders.

Hims & Hers Health Price Performance

NYSE:HIMS opened at $26.02 on Wednesday. Hims & Hers Health, Inc. has a 1 year low of $11.20 and a 1 year high of $72.98. The stock’s fifty day moving average price is $39.53 and its two-hundred day moving average price is $30.15. The company has a market cap of $5.78 billion, a P/E ratio of 59.14 and a beta of 1.65.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings data on Monday, February 24th. The company reported $0.11 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.09 by $0.02. The business had revenue of $481.14 million for the quarter, compared to analysts’ expectations of $494.56 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. On average, analysts expect that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.